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Abstract
Major advances in the conduct of pediatric practice have been reported in the Italian Journal of Pediatrics in 2014. This
review highlights developments in allergy, gastroenterology, infectious diseases, neonatology, nutrition, oncology
and respiratory tract illnesses. Investigations endorse a need to better educate guardians and improve nutritional
management in food allergy. Management of hyperbilirubinemia in neonates and of bronchiolitis have been improved
by position statements of scientific societies. Novel treatments for infant colic and inflammatory bowel diseases have
emerged. Studies suggest the diagnostic utility of ultrasonography in diagnosing community-acquired pneumonia.
Progress in infectious diseases should include the universal varicella vaccination of children. Recommendations on
asphyxia and respiratory distress syndrome have been highlighted in neonatology. Studies have evidenced that
malnutrition remains a common underestimated problem in developing countries, while exposure to cancer risk
factors in children is not negligible in Western countries. Advances in our understanding of less common diseases
such as cystic fibrosis, plastic bronchitis, idiopathic pulmonary hemosiderosis facilitate diagnosis and management.
Researches have led to new therapeutic approaches in patent ductus arteriosus and pediatric malignancies.
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Background
This review focuses on developments in allergology,
gastroenterology, infectious diseases, neonatology, nu-
trition, oncology and respiratory tract illnesses that will
influence the practice of pediatrics. Studies were identi-
fied among the most-accessed articles published in 2014
in the Italian Journal of Pediatrics.
Review
Allergy
Although food allergy is common in childhood, its nutri-
tional management has been given limited prominence
in pediatric research [1]. However, in population-based
studies, growth deficiency and malnutrition have been
shown to be common in children with cow’s milk allergy,
wheat allergy or multiple food allergies [2]. Giovannini
et al. [3] recommend regular visits for updating on nutri-
tional requirements and monitoring growth. They suggest
nutritional interventions and pharmacological supplemen-
tation when dietary modifications are inadequate to meet
vitamin, mineral, and trace element needs. Supplementa-
tion with calcium and vitamin D are generally required in
children with cow’s milk allergy [2]. Giovannini et al. [3]
suggest that a multidisciplinary approach, including the
interaction of nutritionists, dieticians, nurses, allergists
and psychologists, is necessary to ensure growth in food
allergic children and help family members deal with the
exclusion of offending foods. Furthermore, future chal-
lenges include the evaluation and confirmation of dietetic
regimens associated with better clinical outcomes, and the
development of methods for identifying diet-responsive
and nonresponsive phenotypes.
* Correspondence: carlo.caffarelli@unipr.it
1Clinica Pediatrica, Department of Clinical and Experimental Medicine,
University of Parma, Parma, Italy
Full list of author information is available at the end of the article
ITALIAN JOURNAL
OF PEDIATRICS
© 2015 Caffarelli et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Caffarelli et al. Italian Journal of Pediatrics  (2015) 41:84 
DOI 10.1186/s13052-015-0193-8
Gastroenterology
Even though infantile colic is a benign transient condition,
more attention should be given to the high burden of the
affection. A complete understanding of the pathogenesis is
however lacking. Thus, no consensus has been reached on
its management and treatment. Contrasting data have been
reported on the usefulness of maternal milk-free diet or
the use of probiotics on the decrease in daily crying epi-
sodes in these infants [4, 5]. Savino et al. [6] propose differ-
ent dietary approaches based on the type of feeding.
Breast-feeding mothers should go on a milk-free diet for
2 weeks. If the diet does not work, probiotics and pain
relieving agents such as simethicone and cimetropium
bromide should be given. In formula-fed infants, a partially
hydrolyzed formula with prebiotics or probiotics is
suggested. If the treatment is unsuccessful, an extensively
hydrolyzed formula should be administered. Evidence sup-
porting the use of complementary and alternative treat-
ments (herbal supplements, manipulative approach and
acupuncture) or behavioral interventions is limited. The
authors conclude that further studies are required in order
to improve knowledge on infantile colic treatment.
Dysbiosis is characteristic of inflammatory bowel disease
(IBD) and the largest genetic IBD study suggests that
genetic response to the gut microbiome plays a pathogen-
etic role [7]. The microbiota of the gut has an anti-
inflammatory effect on the developing immune system [8].
Comito et al. [9] underline that it is also involved in diges-
tion of dietary components, vitamin synthesis and intes-
tinal motility. An abnormal colonization of the ileal
mucosa is associated with severity and risk of reactivation
of ileal Crohn’s disease [9]. Microbial imbalance causes
low intraluminal levels of butyrate, down-regulation of
epithelial tight junction protein expression and increased
epithelial permeability. This leads to impairment of bac-
teria killing with excessive Toll-like receptor stimulation,
secretion of pro-inflammatory cytokines and activation of
innate and T-cell mediated immune responses with induc-
tion of intestinal inflammation by commensal bacteria and
pathogens [9]. Several genes, such as NOD2, IL-23 R and
ATG16L1 are involved in loss of processing products of
resident intestinal microbiota which may lead to lasting
immune response. Overall, dysbiosis may contribute to
the development of IBD but may also be a result of the
disease. Antibiotic therapy has not been demonstrated to
be effective in the treatment of IBD, except in specific cir-
cumstances. Therefore, changing bacterial populations by
probiotics or fecal microbiota transplantation seem to be
promising treatments in IBD that deserve further investi-
gations [9].
Infectious diseases
The most common neurological complication of varicella
is acute cerebellitis, developing in 1:4000 varicella cases
[10]. The diagnosis of acute cerebellitis is based on the oc-
currence of ataxia following a chickenpox rash within
3 weeks of varicella onset. Bozzola et al. [11] report that
48 (10.5 %) out of 457 children hospitalized for varicella in
a 10 year time interval presented acute cerebellitis. This
rate is in agreement with previous studies. They described
frequency of symptoms. In the 48 cases, symptoms were
as follows: ataxia (95 %), slurred speech (37.5 %), vomiting
(31.25 %), headache (29.16 %), dysmetria (25 %) and
tremor (22.91 %). Nystagmus or other involuntary eye
movements rarely occurred. Even though laboratory in-
vestigations are not considered necessary for diagnosis,
three patients underwent a lumbar puncture, 18 magnetic
resonance imaging and two computed tomography. Such
investigations, however, did not show relevant findings. In
addition to intravenous acyclovir, 33 % of subjects received
systemic steroids that did not improve symptoms. At the
2-month follow-up, one child showed persistent uninten-
tional tremors. No child in the study population had
received the varicella vaccine. This reflects low vaccination
coverage in the region from which the patients included
in the study came from. These data concur to demonstrate
that universal varicella vaccination of children is beneficial
not only in the perspective of preventing varicella compli-
cations but also in reducing societal costs [12].
Community-acquired pneumonia (CAP) is the most
common disease recorded worldwide. The diagnosis is
established, in an appropriate clinical setting, by the finding
of a new pulmonary infiltrate on chest radiograph. Lung
ultrasound represents a new technique used for diagnosing
pleural and pulmonary diseases [13]. It is a noninvasive
tool, and is usually available in most hospitals. This is espe-
cially important if radiography is not available or applic-
able, and only 8 % of pneumonic lesions are not detected
by lung ultrasound [14]. Presently only few prospective
studies on point-of-care ultrasonography (US) in pediatric
CAP have been published. In particular, very few data on
the efficacy of US compared to conventional chest radiog-
raphy (CR) in defining different types of lung abnormalities
have been reported. According to recent guidelines, the
diagnosis of mild to moderate cases of pediatric CAP can
be based solely on clinical criteria, whereas CR is required
in severe cases which need hospitalization and/or when
complications are suspected. The absence of CR confirm-
ation leads to an overestimation of the incidence of CAP
causing a number of problems, the most important of
which being an increased use of unnecessary antibiotics. In
an attempt to overcome this problem, US was proposed in
1986, but only recently technological advances revived the
interest in US as a diagnostic tool for lower respiratory
tract infections. A number of studies have shown that it is
feasible and accurate if used by experienced clinician-
sonologists, but there are still few prospective evaluations
of point-of-care US for the diagnosis of pediatric CAP.
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Esposito et al. [15] prospectively studied 103 children who
were admitted to the hospital with a clinical suspicion of
CAP. Patients underwent CR (evaluated by an independ-
ent expert radiologist) and lung US (performed by a
resident in pediatrics with limited experience in US). The
accuracy of US in diagnosing CAP (i.e. its sensitivity, spe-
cificity, and positive and negative predictive values) was
compared with that of CR. Forty-eight of the 103 enrolled
children had radiographically confirmed CAP. The find-
ings of this study confirm that lung US is a simple and
reliable technique that is nearly as reliable as CR in identi-
fying lung changes that are diagnostic for CAP, and shows
that it is even more effective than CR in diagnosing
pleural effusion. These data further support recent recom-
mendations of the International Liaison Committee on
Lung Ultrasound on the use of US in pediatric patients
with suspected CAP in order to reduce antibiotic abuse.
US has a number of advantages: it is easy to perform at a
child’s bedside, takes little time to perform and interpret
results, allows a close follow-up and avoids the use of
ionising radiation, which is particularly important in chil-
dren who are at least four times more sensitive than adults
to the induction of cancer. The concordance of the US
and CR data was relatively limited in terms of type of lung
lesion revealed, and this may have important implications
when an antibiotic prescription is indicated. US may be
considered as a useful means of diagnosing CAP in chil-
dren admitted to an Emergency Department with lower
respiratory tract infections. However, its usefulness in
identifying the type of lung involvement is uncertain and
may be influenced by the operator’s learning curve. Fur-
ther evaluations are necessary before US is recommended
in the decision making process concerning treatment of
pediatric CAP.
Mycoplasma pneumoniae (MP) causes up to 40 % of
community-acquired pneumonia (CAP) in children and
about 18 % of infections in patients who require
hospitalization. Compared with non-mycoplasma infec-
tions, CAP patients infected with MP are younger, less
likely to have comorbidities and present a longer dur-
ation of fever before admission. In the majority of cases
of suspected MP pneumonia, the presumptive diagnosis
is performed on clinical and radiological findings alone.
The study of Medjo et al. [16] included 166 children
aged between 1 and 15 years with radiologically con-
firmed pneumonia. Authors showed that there were no
characteristic radiological findings or routine labora-
tory tests that distinguished CAP caused by MP from
other organisms. MP infection was more present in
boys than in girls (p = 0.014). Children with MP pneu-
monia were significantly older (p = 0.001) and had
longer duration of fever (p = 0.021) and cough before
enrolment (p = 0.026) compared to those with non-MP
pneumonia. Cough (p = 0.029), headache (p = 0.001)
and wheezing (p = 0.036) were more frequent in children
with MP pneumonia compared to other cases. Detection
of IgM antibodies combined with real-time PCR allows a
precise and reliable diagnosis of MP infection in children
during the early acute phases of the disease, indicating a
possible use of both techniques as a valid diagnostic ap-
proach. A recent study found a good agreement between
positive rate of MP cultivation of throat swabs and acute
MP infection, and concluded that the logical approach
would be to incorporate PCR, culture and serological tests
for optimum diagnosis of acute MP infections in adults
and adolescents [17]. A systematic review showed that the
presence of chest pain more than doubles the probability
of MP pneumonia [18]. However, further research is
needed to substantiate this finding. More high quality
large-scale studies in primary care settings are needed to
help develop prediction rules based on epidemiological
data as well as clinical and baseline patient characteristics.
Neonatology
Birth asphyxia represents a serious problem worldwide
and contributes greatly to neonatal mortality and mor-
bidity. According to the WHO, 4 million deaths that
occur yearly are due to birth asphyxia, representing 38 %
of all deaths in children <5 years of age. Among different
countries, prevalence of birth asphyxia greatly varies in
relation with socio-economical level [19]. Birth asphyxia
is strongly associated with intrapartum stillbirth and is
responsible for long-term neurological disability and
impairment. Asiam et al. [20] conducted a retrospective
case control study from January 2011 to November 2012
in the neonatal intensive care unit of the Civil Hospital
of Karachi, Pakistan which aimed to evaluate antepar-
tum, intrapartum, and fetal risk factors of birth asphyxia.
The study evidenced maternal age, pre-eclampsia, and
diuretic or adrenergic drug use as maternal risk factors.
Intrapartum risk factors included home delivery by mid-
wives, breech presentation, prolapsed umbilical cord,
cephalopelvic disproportion and maternal fever. Prema-
turity, low birth weight, oligohydromnios, and meconium
stained amniotic fluid were evidenced as fetal risk factors.
This study emphasizes that the majority of these risk fac-
tors may be manageable by means of good pre-natal care.
There is a need of interventions that focus on educating
mothers during the antenatal period to reduce potential
risk factors for mortality, especially in resource-limited
settings [21].
A persistently patent ductus arteriosus (PDA) has sig-
nificant clinical consequences in preterm neonates during
the recovery period from respiratory distress syndrome.
Ductal patency is regulated by circulating prostaglandins
produced by prostaglandin-H2 synthetase, an enzyme
which is composed of two active sites: cyclo-oxygenase
(COX) and peroxidase. Indomethacin and ibuprofen are
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COX inhibitor drugs that are commonly used in the treat-
ment of hemodynamically significant PDA. These drugs are
however often associated in early life with serious adverse
events, including gastrointestinal perforation, renal failure
and bleeding. There is increasing interest in the role of
paracetamol, an inhibitor of the peroxidase component of
prostaglandin-H2 synthetase, for the treatment of PDA in
the last few years following the first published case report
in 2011 [22]. Terrin et al. [23] aimed to evaluate the efficacy
of paracetamol in the early treatment of PDA in preterm
neonates presenting contraindications to COX-inhibitors.
In their series of eight neonates successful closure of the
ductus arteriosus was achieved in six out of 8 babies (75 %)
treated with paracetamol. On the basis of these results, the
Authors state that paracetamol may be considered as a
promising and safe choice in the treatment of PDA in neo-
nates. Their findings are in agreement with results of con-
trolled trials demonstrating that paracetamol and ibuprofen
have similar efficacy in PDA treatment [24, 25].
Kangaroo mother care (KMC) is a method of holding a
neonate in skin-to-skin contact, prone upright on the ma-
ternal chest. This method promotes health effects for both
the mother and baby, including a decrease in morbidity
and mortality, increase in breastfeeding, weight gain and
mother-baby bonding. To date, most studies on KMC have
addressed cardiorespiratory parameters rather than cere-
bral hemodynamics. Afaf et al. [26] evaluated the changes
of cerebral blood flow in the middle cerebral artery, before
and after a 30 min application of KMC in stable preterm
infants. They evidenced an improvement in cerebral blood
flow, within its normal level, with a significant decrease in
both Pulsatility index and Resistive index after 30 min of
KMC. This suggests a positive influence on the structure
and development of the premature infant’s brain. Clinical
evidence shows the usefulness of KMC in low birth weight
infants as an alternative to conventional neonatal care
mainly in developing countries [27]. However, KMC is
physically and emotionally difficult, thus its practice needs
to be supported by family members and health practi-
tioners [28].
Nutrition
Malnutrition is an unbearable burden not only on health
systems, but on the entire socio-cultural and economic
status of society, constituting a major public health prob-
lem in developing countries and contributing significantly
to morbidity and mortality especially among preschool
children. Globally, it is estimated that nearly 20 million
children are severely malnourished, most of them living in
south Asia and in sub-Saharan Africa. Worldwide malnu-
trition estimation rates indicate that 35.8 % of preschool
children in developing countries are underweight, 42.7 %
are stunted, and 9.2 % are wasted [29].
Manyike et al. [30], in a cross-sectional study, aimed to
assess the prevalence of malnutrition and associated fac-
tors among children aged 1–5 years attending nursery and
primary schools in Abakiliki in Ebonyi state of Nigeria.
Anthropometry and clinical examination was performed
and malnutrition was defined as a state of nutrition where
weight for age, height for age and weight for height indices
were below −2 Z-score of the NCHS references. The
prevalence of global and severe acute malnutrition using
z-score in the study was 9.7 and 4.4 % respectively while
that of stunting was 9.9 % with a male preponderance. Re-
duced survival, increased incidence of acute and chronic
diseases and impaired healthy development caused by
malnutrition should lead to interventions that focus on
effective nutrition programs [31].
Oncology
The incidence of all cancers occurring in children under
20 years of age is about 175 cases per million in the United
States, with an incidence of many individual types in the
low dozens [32]. Rarity is thus a central factor which dic-
tates the quality and quantity of evidence for causal associ-
ations between putative risk factors and childhood cancers.
Most etiologic investigations on childhood cancer have
therefore used the case–control study design, in which the
characteristics of patients with a disease are compared to
those of a carefully selected group of disease-free controls.
Given the milieu for childhood cancer epidemiology,
evidence regarding causal associations has accumulated
slowly, and etiology of childhood leukaemia and childhood
neoplasm is still poorly understood. Information on the
prevalence of risk factors in the pediatric population is lim-
ited as well. A multicenter, population-based case–control
epidemiological study (SETIL - Studio Epidemiological
Study on lymphoemopoietic cancers in childhood) was car-
ried out to investigate risk factors for selected childhood
neoplasms in Italy [33]. The primary study focused on leu-
kaemia and was accompanied by two smaller studies on
NHL and neuroblastoma. The study relied on question-
naire interviews and 50 Hz magnetic field (ELF-MF) indoor
measurements. SETIL was carried out in 14 Italian regions
(Piedmont, Liguria, Lombardy, The Venetian Region,
Friuli Venezia Giulia, Emilia Romagna, Tuscany, Umbria,
The Marches, The Latium, Campania, Apulia, Sicily and
Sardinia). Cases of leukaemia, non-Hodgkin Lymphoma
(NHL) and neuroblastoma in children aged 0–10 years
and diagnosed between August 1998 and December 2001
(with minor regional differences) were eligible for recruit-
ment. Two controls for each leukaemia case were ran-
domly sampled from the Local Health Authority records,
matched by gender, birthdate and residence. The same
controls were used in NHL and neuroblastoma studies.
Parents were interviewed at home on: physical agents
(ELF-MF and ionizing radiation), chemicals (smoking,
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solvents, traffic, insecticides), occupation, medical and per-
sonal history of children and parents, infectious diseases,
immunizations and associated factors. Occupational expos-
ure was collected using job specific modules. ELF-MF was
measured in the main rooms (spot measurement) and
close to child’s bed (48 h measurements). The results
showed that in Italian children the exposure to cancer risk
factors is not negligible, and this appears to be consistent
with data from other countries of Western lifestyle and
industrial economy. Few environmental risk factors for
childhood cancer have been identified in which observa-
tional epidemiology is able to distinguish between causal
associations and associations due to bias [34]. Therefore,
the association of common risk factors such as smoking
with childhood leukemia is debated, even if they clearly
represent risk factors for other diseases in childhood, such
as asthma and acute respiratory illness.
Respiratory tract illnesses
Viral bronchiolitis is the most frequent lower respiratory
tract infection in infants and Respiratory Syncytial Virus
(RSV) is the most common infecting agent, but other
respiratory viruses may occasionally cause the disease as
co-infecting agents. Bronchiolitis is the leading cause of
hospitalization among infants during the first 12 months
of life (with a peak of hospitalization at the age of
2 months), and a number of these children require admis-
sion to intensive care units and mechanical ventilation.
Severe forms of the disease requiring hospitalization may
be more frequent in children younger than 3 months of
age or in children with pre-existing risk factors such as
prematurity, bronchopulmonary dysplasia, congenital
heart disease and immunodeficiency. In October 2006,
the American Academy of Pediatrics published the clin-
ical practice guideline “Diagnosis and Management of
Bronchiolitis” [35]. The guideline offered recommenda-
tions ranked according to level of evidence and benefit-
harm relationship. Since the completion of the original
evidence review in July 2004, a significant body of litera-
ture on bronchiolitis has been published. However,
there is no evidence of efficacy for numerous therapies
commonly used when treating bronchiolitis (bronchodi-
lators, steroids, antibiotics), and supportive treatment
(oxygen and hydration) still remains the recommended
approach, as confirmed by the very recent leading inter-
national guideline [36].
An intersociety consensus document [37] from Italy pro-
vides a multidisciplinary update for the National Health
System (NHS), pediatricians working in hospital and emer-
gency departments, primary care pediatricians, physicians
attending postgraduate schools, nurses and all healthcare
providers in the pediatric area, concerning scientific evi-
dence on treatment and prevention of bronchiolitis, with a
special focus on high risk pediatric populations. Authors
will update the document every 3 years. Baraldi et al. [37]
point out that milder forms of bronchiolitis may be ad-
equately managed in the outpatient setting by primary care
pediatricians, thus limiting hospital admissions. In the out-
patient setting the child’s general clinical conditions must
be assessed, together with his/her ability to feed, heart rate,
respiratory rate, oxygen saturation (measured by pulse ox-
imetry with specific sensors for infants), presence of risk
factors and family compliance. Hospitalization is warranted
based on the following conditions: O2 saturation persist-
ently lower than 90–92 %, entity of respiratory distress and
presence of apnea. Other important factors to take into
consideration are: prematurity, gestational age <37 weeks
or birth age <6–12 weeks, responsivity and alertness,
decreased hydration and feeding, and preexisting chronic
disorders. Children with severe bronchiolitis must be trans-
ferred to the Pediatric Intensive Care Unit, based on the
following conditions: respiratory failure requiring mechan-
ical ventilation, apnea with desaturation, severe impair-
ment of general conditions. Criteria that must be taken
into account for patients’ discharge include: sustained au-
tonomy from any kind of respiratory support and O2 satur-
ation levels >92–94 % at room air, stabilization of clinical
presentation, adequate oral intake of fluids and feeds
(>75 %), adequacy of the family unit in terms of providing
monitoring and possible continuation of therapy at home,
possibility, if necessary, of obtaining pediatric health care
assistance locally. To date, there is no specific treatment
for viral bronchiolitis, and the mainstay of therapy is sup-
portive care, i.e. nasal suctioning and nebulized 3 % hyper-
tonic saline, assisted feeding and hydration, humidified O2.
The possible role of any pharmacological approach is still
debated, and until now there is no evidence to support the
use of bronchodilators, corticosteroids, chest physiother-
apy, antibiotics or antivirals. Nebulized adrenaline may
sometimes be useful in the Emergency Room. Since a
specific etiological treatment is lacking, prophylaxis and
prevention, especially in children at high risk of severe
infection, play a fundamental role. Environmental pre-
ventive measures minimize viral transmission in the
hospital, in the outpatient setting and at home. Pharma-
cological prophylaxis with palivizumab for RSV bron-
chiolitis is indicated in specific categories of children at
risk during the epidemic period.
The inter-society consensus document [37] on treat-
ment and prevention of bronchiolitis is an important tool
for pediatricians and neonatologists. Considering the pau-
city of critical care research in pediatric viral bronchiolitis,
intensive care practitioners must substantially rely on
individualization of therapies based on bedside clinical
assessments. However, with the introduction of new diag-
nostic and respiratory technologies, our ability to support
critically ill infants with acute viral bronchiolitis will con-
tinue to advance.
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Plastic bronchitis (PB) is a rare complication of a
variety of respiratory diseases that may secondarily com-
plicate the post-operative course of Fontan surgery in
patients with cyanotic congenital heart disease (CHD).
Bronchial casts with rubber-like consistency develop
acutely and may cause severe life-threatening distress.
The pathophysiology of PB remains to be elucidated,
and its management is not yet well defined. It has been
suggested that high pulmonary venous pressures may
lead to an abnormal response from the respiratory
epithelium and/or lymphatic dysfunction, thus resulting
in excess mucus production and cast formation [38]. An
underlying genetic predisposition associated with an
inflammatory trigger has also been postulated to explain
the abnormal mucin hypersecretion. PB has been classi-
fied in type 1 (inflammatory) and type 2 (noninflamma-
tory) according to the characteristics of casts. Colaneri
et al. [39] report the case of an adolescent with CHD
and primary ciliary dyskinesia (PCD) who developed
features of PB and severe respiratory failure 7 years after
Fontan operation. The occurrence of PB in this patient
permitted to hypothesize that decreased mucociliary
clearance was an adjunctive trigger for the development
of PB. Seven years after the Fontan operation the patient
was admitted to the Intensive Care Unit because of
severe respiratory distress, with scattered, harsh breath
sounds at chest auscultation. Arterial blood gas analysis
showed pH 6.9, PaO2 61 mmHg, SaO2 88 %, PaCO2
150 mmHg, and the patient was immediately mechanic-
ally ventilated. Chest radiograph (CR) revealed patchy
consolidation in the right middle lobe and mild pleural
effusion. A flexible fiberoptic bronchoscopy revealed
large, mucinous casts partially obstructing the airway
tree, and rigid bronchoscopy was necessary to remove
the casts. An immediate improvement in oxygenation
was obtained. Histological examination revealed mostly
mucous material with fibrin and rare inflammatory cells.
Cultures taken from the casts were negative. Mechanical
ventilation was withdrawn on hospital day 12. Treatment
with nebulized tissue plasminogen activator (t-PA) was
added. Over the next few days, the child started expec-
torating thinner bronchial secretions and his condition
improved gradually, with clearing of areas of atelectasis
and no recurrence of respiratory symptoms. The patient
was discharged receiving t-PA 5 mg for four times daily
by nebulisation for 2 months. The patient received
instructions to reintroduce a course of t-PA at the re-
onset of symptoms or signs (cough, expectoration or
chest discomfort). During the 12 month follow-up, this
therapeutic regimen was reintroduced eight times with
complete relief, no side effects and no further hospital
admission underlining that this regimen may be useful
in Fontan patients with plastic bronchitis refractory to
conventional therapy [40].
Idiopathic pulmonary hemosiderosis (IPH) is a rare dis-
order responsible for recurrent episodes of diffuse alveolar
haemorrhage, characterized by the triad of hemoptysis, iron
deficiency anemia and diffuse pulmonary infiltrates. The
clinical course is exceedingly variable especially in children,
and a substantial proportion of this age group remains
undiagnosed. The rarity of this disease and the variable
clinical course results in many diagnostic pitfalls especially
in children. This is probably due to the fact that iron defi-
ciency anemia may be the first and only manifestation of
IPH, preceding other symptoms and signs by several
months. Delayed diagnosis of IPH favours complications
and the start of treatment at a stage when pulmonary fibro-
sis has already developed, with a consequently poorer prog-
nosis. Bakalli et al. [41] report the case of a 13 year-old girl
who, at admission, appeared very pale, with extreme tired-
ness, inability to stay upright. Dyspnea and tachypnea with
very low oxygen saturation (SaO2) in room air (78 %), and
low systemic blood pressure (80/40 mmHg) were also
present. For several months the girl had been treated for
iron deficiency anemia with oral iron salts with no re-
sponse. The child’s condition deteriorated rapidly with sig-
nificant respiratory failure. Chest X-ray evidenced bilateral
alveolar infiltrates. CT images associated with the presence
of hemosiderin-laden macrophages called siderophages
(pathognomonic of this disease) in gastric lavage fluid con-
firmed the diagnosis of IPH. Therapy with corticosteroids
was started with a partial and transient response. The girl
presented recurrent episodes of dyspnea and severe anemia
every 2 to 3 months. Due to prolonged therapy, her aspect
became progressively cushingoid. Azathioprine, the “second
line” immunosuppressant recommended in IPH, was sub-
sequently introduced, and the girl’s clinical condition
progressively improved. The triad of iron deficiency
anemia, hemoptysis and diffuse infiltrates on chest - X ray
characterizes the onset of IPH. The clinical course of the
disease is exceedingly variable, especially in children. The
age of presentation may be bimodal, with a peak in children
younger than 5 years of age and in adolescents. Anemia is
hypochromic and microcytic, due to the chronic loss of
blood. Failure of iron therapy and exclusion of its common
causes, prompted authors to consider other diagnostic
possibilities including IPH, even though the latter is a rare
cause of anemia. Diagnosis of IPH is based on exclusion of
other causes of intrapulmonary haemorrhage and systemic
diseases. When children present with unexplained anemia
and bilateral lung infiltrations, pulmonary haemorrhage
should be suspected [42]. In the absence of systemic
disease, findings of hemosiderin-laden macrophages in
bronchoscopic lavage or gastric aspirate/sputum along with
chronic pulmonary symptoms lead to a diagnosis of IPH.
Lung biopsy is the gold standard for diagnosis. HRCT scan
is useful for early detection of pulmonary fibrosis. It has
been reported that steroid treatment is associated with
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decreased pulmonary bleeding relapses and pulmonary
fibrosis. Immunosuppressive therapies, mainly azathioprine
and hydroxychloroquine, are generally prescribed in
patients with steroid-refractory disease. Since there is a lack
of large patient series and inadequate follow-up in previous
studies, the prognosis of IPH remains unclear. However,
aggressive treatment is associated with prolonged survival
and improved prognosis [43].
There is growing recognition that patient-reported out-
comes, such as health-related quality of life (HRQoL), are
important indicators of patient benefit in clinical trials [44].
This is particularly true for patients with chronic illnesses
such as cystic fibrosis (CF), in which disease management
is both challenging and lifelong. Patients with CF are main-
taining greater lung function and enjoying longer life
expectancy; thus, the need for clinical trial end points in
addition to pulmonary function indexes is becoming more
critical. It has been demonstrated that CF has a significant
impact on patients’ HRQoL [45] At present the primary
goal of CF physicians is not only to extend patients’ life but
also to improve their quality of life. The multicenter study
from Bodnar et al. [46] intended to investigate the relation-
ships between demographic variables, disease severity,
pulmonary variables, nutritional status and HRQoL in CF
patients, and, finally to assess the level of agreement of
HRQoL scores between children/adolescents with CF and
their parents. Fifty-nine CF patients from five Hungarian
CF centers completed the survey. HRQoL was measured
using The Cystic Fibrosis Questionnaire-Revised (CFQ-R).
Parents were asked to fill out a questionnaire on their
smoking habits, educational level and history of chronic
illnesses. Disease severity was assessed using the physician-
reported Shwachman-Kulczycki (SK) score system. Spirom-
etry, Body Mass Index (BMI) percentile (pc), hospitalization
and Pseudomonas aeruginosa (PA) infection were exam-
ined as physiologic parameters of CF, and the impact of
these factors on HRQoL was also assessed. As far as the re-
sults, passive smoking, parental educational level and
chronic diseases of parents did not affect the HRQoL of CF
patients. In contrast, hospitalization, PA infection and mal-
nutrition had a significant and negative impact on patients’
HRQoL and clinical severity of the disease. There is grow-
ing recognition that patient-reported outcomes, such as
HRQoL, are important indicators of patient benefits. This
is particularly true for patients with chronic illnesses such
as CF, in which disease management is both challenging
and lifelong. The evaluation of HRQoL provides additional
information for clinicians and is a promising additional end
point for clinical trials that may translate into better treat-
ment adherence and improved clinical outcomes.
Conclusions
This synopsis of advances in pediatrics in 2014 provides in-
dications on standards of care, environmental risk factors,
mechanisms, novel tests to facilitate diagnosis and new
treatment options. Position statement of scientific societies
on the management of bronchiolitis is an important
support for improving its management. Malnutrition re-
mains a common underestimated problem that requires
urgent actions in developing countries. On the other hand,
children in Western countries are exposed to cancer risk
factors, and this appears consistent with data from Italy.
Important progresses have emerged regarding etio-
pathogenic mechanisms and possible management and
treatment in infantile colic and inflammatory bowel
disease. Diagnostic tests are improving, and early studies
suggest the diagnostic utility of US in diagnosing CAP.
Investigations suggest a need to better educate guardians
and improve nutritional management of food allergy.
Insights on clinical features and pathogens emphasized the
preventive role of varicella vaccine in acute cerebellitis,
and of MP in CAP. Recommendations on asphyxia and
KMC in neonates have been highlighted. Insights in treat-
ments have evidenced benefits from paracetamol in PDA.
Advances in our understanding of less common diseases
such as cystic fibrosis, plastic bronchitis, and IPH facilitate
diagnosis and management.
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